UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a‑16 OR 15d‑16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
FOR THE MONTH OF MAY 2024
COMMISSION FILE NUMBER 001-39081
BioNTech SE
(Translation of registrant’s name into English)
(Translation of registrant’s name into English)
An der Goldgrube 12
D-55131 Mainz
Germany
+49 6131-9084-0
(Address of principal executive offices)
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20‑F or Form 40‑F: Form 20‑F ☒ Form 40‑F ☐
Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6‑K in paper as permitted by Regulation S‑T Rule 101(b)(7): ☐
DOCUMENTS INCLUDED AS PART OF THIS FORM 6-K
On May 17, 2024, BioNTech SE (the “Company”) held the Annual General Meeting (“AGM”) 2024. The press release and the AGM presentation are attached hereto as Exhibits 99.1 and 99.2, respectively. The voting results are attached hereto as Exhibit 99.3.
SIGNATURE
Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| BioNTech SE | ||||||||
| By: | /s/ Dr. Sierk Poetting | |||||||
| Name: Sierk Poetting | ||||||||
| Title: Chief Operating Officer | ||||||||
Date: May 17, 2024
EXHIBIT INDEX
| Exhibit | Description of Exhibit | ||||
| 99.1 | |||||
| 99.2 | |||||
| 99.3 | |||||
Exhibit 99.1
BioNTech SE Shareholders Approve All Agenda Items at the
Annual General Meeting 2024
MAINZ, Germany, May 17, 2024 (GLOBE NEWSWIRE) — BioNTech SE (Nasdaq: BNTX, “BioNTech” or the “Company”) held its Annual General Meeting (“AGM”) today, May 17, 2024. A total of 87.51 per cent of the share capital was represented at the virtual assembly. There were 14 items on the agenda of the AGM. All resolutions proposed on the agenda items put to the vote at today’s AGM were approved by a large majority of the shareholders.
“The past few years marked a leap in competence for BioNTech,” said Helmut Jeggle, Chairman of the Supervisory Board of BioNTech. “With the development and commercialization of a leading COVID-19 vaccine, BioNTech has shown that it can deliver against targeted objectives successfully. Today, BioNTech’s robust financial position is an excellent foundation for its transformation into a multi-product company, with particular focus on achieving commercial readiness in oncology.”
“2023 was a year in which we made important progress in many areas: We maintained a leading position in the COVID-19 vaccine market, published encouraging data for candidates in our oncology pipeline and launched potentially registrational trials. Additionally, we have strengthened our organization in preparation for the next phase of growth, particularly with regards to our planned product launches in oncology,” said Prof. Ugur Sahin, M.D., CEO and Co-Founder of BioNTech. “We believe that our therapies under development, once approved, have the potential to complement or replace established cancer treatment approaches in many areas in the future.”
The voting results for all agenda items can be seen on the Annual General Meeting 2024 website under the section ‘Voting Results’. The speech by Prof. Ugur Sahin, M.D., and the slides presented at the AGM 2024 can be found in section ‘Speeches and Presentations’ under the same link.
About BioNTech
Biopharmaceutical New Technologies (BioNTech) is a global next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. BioNTech exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor (CAR) T cells, several protein-based therapeutics, including bispecific immune checkpoint modulators, targeted cancer antibodies and antibody-drug conjugate (ADC) therapeutics, as well as small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global and specialized pharmaceutical collaborators, including Biotheus, DualityBio, Fosun Pharma, Genentech, a member of the Roche Group, Genevant, Genmab, MediLink, OncoC4, Pfizer and Regeneron.
For more information, please visit www.BioNTech.com.
Forward-Looking Statements
This press release contains “forward-looking statements” of BioNTech within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements may include, but may not be limited to, statements concerning BioNTech’s financial position; BioNTech’s research and development programs, including statements characterizing timing, related preparatory work, and the availability of results; and BioNTech’s preparations for potential product launches in oncology. Any forward-looking statements in this press release are based on BioNTech’s current expectations and beliefs of future events. The forward-looking statements in this press release are neither promises nor guarantees, and you should not place undue reliance on these forward-looking statements because
1
they involve known and unknown risks, uncertainties, and other factors, many of which are beyond BioNTech’s control, and which could cause actual results to differ materially from those expressed or implied by these forward-looking statements.
You should review the risks and uncertainties described under the heading “Risk Factors” in BioNTech’s Report on Form 6-K for the period ended March 31, 2024 and in subsequent filings made by BioNTech with the SEC, which are available on the SEC’s website at www.sec.gov. These forward-looking statements speak only as of the date hereof. Except as required by law, BioNTech disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release in the event of new information, future developments or otherwise.
CONTACTS
Investor Relations
Victoria Meissner, M.D.
+1 617 528 8293
Investors@biontech.de
Media Relations
Jasmina Alatovic
+49 (0)6131 9084 1513
Media@biontech.de
2
Annual General Meeting (AGM) 17 May 2024 Exhibit 99.2
Management Report 2 Financial Development 2023 & Q1 2024 und Financial Outlook 2024 Jens Holstein, Chief Financial Officer 1 Operations Development 2023 & Q1 2024 and Outlook 2024 Prof. Dr. Ugur Sahin, Chief Executive Officer & Co-Founder
1 Operations Development 2023 & Q1 2024 and Outlook 2024 Prof. Dr. Ugur Sahin, CEO & Co-Founder
This Slide Presentation Includes Forward-Looking Statements 4 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: BioNTech’s expected revenues and net profit/(loss) related to sales of BioNTech’s COVID-19 vaccine, referred to as COMIRNATY where approved for use under full or conditional marketing authorization, in territories controlled by BioNTech’s collaboration partners, particularly for those figures that are derived from preliminary estimates provided by BioNTech’s partners; the rate and degree of market acceptance of BioNTech’s COVID-19 vaccine and, if approved, BioNTech’s investigational medicines; expectations regarding anticipated changes in COVID-19 vaccine demand, including changes to the ordering environment and expected regulatory recommendations to adapt vaccines to address new variants or sublineages; the initiation, timing, progress, results, and cost of BioNTech’s research and development programs, including BioNTech’s current and future preclinical studies and clinical trials, including statements regarding the timing of initiation, enrollment, and completion of studies or trials and related preparatory work and the availability of results, and the timing and outcome of applications for regulatory approvals and marketing authorizations; the targeted timing and number of additional potentially registrational trials, and the registrational potential of any trial BioNTech may initiate; discussions with regulatory agencies; BioNTech’s expectations with respect to intellectual property; the impact of BioNTech’s acquisition of InstaDeep Ltd. and its collaboration and licensing agreements; the development, nature and feasibility of sustainable vaccine production and supply solutions; and BioNTech's estimates of revenues, research and development expenses, selling, general and administrative expenses, and capital expenditures for operating activities. In some cases, forward-looking statements can be identified by terminology such as “will,” “may,” “should,” “expects,” “intends,” “plans,” “aims,” “anticipates,” “believes,” “estimates,” “predicts,” “potential,” “continue,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. The forward-looking statements in this presentation are based on BioNTech’s current expectations and beliefs of future events, and are neither promises nor guarantees. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, many of which are beyond BioNTech’s control and which could cause actual results to differ materially and adversely from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as risks associated with preclinical and clinical data, including the data discussed in this release, and including the possibility of unfavorable new preclinical, clinical or safety data and further analyses of existing preclinical, clinical or safety data; the nature of the clinical data, which is subject to ongoing peer review, regulatory review and market interpretation; BioNTech’s pricing and coverage negotiations regarding its COVID-19 vaccine with governmental authorities, private health insurers and other third-party payors; the future commercial demand and medical need for initial or booster doses of a COVID-19 vaccine; competition from other COVID-19 vaccines or related to BioNTech’s other product candidates, including those with different mechanisms of action and different manufacturing and distribution constraints, on the basis of, among other things, efficacy, cost, convenience of storage and distribution, breadth of approved use, side-effect profile and durability of immune response; the timing of and BioNTech’s ability to obtain and maintain regulatory approval for its product candidates; the ability of BioNTech’s COVID-19 vaccines to prevent COVID-19 caused by emerging virus variants; BioNTech’s and its counterparties’ ability to manage and source necessary energy resources; BioNTech’s ability to identify research opportunities and discover and develop investigational medicines; the ability and willingness of BioNTech’s third-party collaborators to continue research and development activities relating to BioNTech's development candidates and investigational medicines; the impact of COVID-19 on BioNTech’s development programs, supply chain, collaborators and financial performance; unforeseen safety issues and potential claims that are alleged to arise from the use of products and product candidates developed or manufactured by BioNTech; BioNTech’s and its collaborators’ ability to commercialize and market BioNTech’s COVID-19 vaccine and, if approved, its product candidates; BioNTech’s ability to manage its development and expansion; regulatory developments in the United States and other countries; BioNTech’s ability to effectively scale its production capabilities and manufacture its products and product candidates; risks relating to the global financial system and markets; and other factors not known to BioNTech at this time. You should review the risks and uncertainties described under the heading “Risk Factors” in BioNTech’s Report on Form 6-K for the period ended March 31, 2024 and in subsequent filings made by BioNTech with the SEC, which are available on the SEC’s website at www.sec.gov. These forward- looking statements speak only as of the date hereof. Except as required by law, BioNTech disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this presentation in the event of new information, future developments or otherwise.
Our Vision Using the full potential of the immune system to develop new immunotherapies and vaccines
Our Vision: Harnessing the Power of the Immune System to Fight Human Disease 6 AI = artificial intelligence. Innovative precision medicine pipeline targeting multiple product approvals in oncology in the coming years Multi-product immunotherapy pioneer addressing medical need worldwide Sustainable respiratory vaccine business Powered by breakthrough science, disruptive technologies & AI BioNTech’s key objectives for the next phase Elevating success beyond our historical achievement
Diversified Oncology Pipeline
Intraindividual variability & intratumoral heterogeneity driving evasion and secondary resistance mechanism Root Cause of Cancer Treatment Failure Cancer cells Genetically diverse & adaptable5-20 Years – up to 10,000 mutations Mutations DNA Mutation Healthy Cell Mutations Mutations Mutations Mutations Individual patients 8 Tumor Cell Alexandrov L et al., Nature 2019; Kandoth C et al., Nature 2013; Yizhak K et al., Science 2019; Lim Z & Ma P, J Hematol Oncol 2019; Quazi MA et al., Ann Oncol 2017; Maryusk A et al., Cancer Cell 2023.
Towards a Potentially Curative Approach to Cancer: Differentiated Combinations Space for potentially curative approaches Immunomodulators Novel checkpoint inhibitors, cytokines, immune agonists mRNA vaccines Targeted therapy ADCs, CAR-T, TCR-T, small molecules SynergySynergy Synergy 9 CAR = chimeric antigen receptor; ADC = antibody-drug conjugate; IO = immune oncology; TCR-T = T-cell receptor engineered T cell. Immunomodulators • Focus on the most relevant and crucial IO pathways • Targeting different complementary players in the complex cancer immunity cycle may promote a thorough and durable anti-tumor effect mRNA cancer vaccines • Could eliminate polyclonal residual disease with individualized vaccines for potential long-term impact • Polyspecific activity by targeting multiple antigens at once Targeted therapy • Potent and precise therapies could rapidly reduce tumor burden • Designed to have clinical efficacy across the entire disease continuum including late lines
Investing Through Waves of Innovation with the Aim to Transform Cancer Treatment 10 mRNA cancer vaccines ADCs Immunomodulators Cell Therapy Mid Term 1st wave of oncology launches planned from 2026 onwards Unlock value with initial combination trials Expanding across indication and treatment lines Long Term Goal of 10 indication approvals in oncology by 2030 Initial launches of 2nd wave products Oncology strategy offering multiple shots on goal 10+ mid- to late- stage trials in 2024: Near Term ADC – antibody-drug conjugate
Sustainable Pipeline for COVID-19 and Other Infectious Diseases
We Made History 12 1. Ball P. Nature. 2021; 2. Measured by sales recorded for a single product in a single year (>$40 billion combined of direct sales recorded by Pfizer or BioNTech in both 2021 and 2022); 3. Cumulative doses shipped in the years 2021, 2022 and 2023. 4. COVID-19 Excess Mortality Collaborators. Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020-21. Lancet. 2022. 5. Kirson N. J Med Econ. 2022. > 4.8 billion doses of BNT162b2 shipped > 180 countries and territories3 COVID-19 vaccines estimated to have reduced deaths by at least 57%, saving more than 1.4 million lives in WHO European Region alone4 Trillions of dollars of global economic impact in the United States alone5 The fastest vaccine development in the history of medicine1 The strongest launch of any pharmaceutical product2 Saved lives and impacted the global economy
Variant-adapted vaccines Designed to be effective against multiple variants of concern5 Long-term health consequences Accumulating evidence demonstrates that COVID-19 vaccination reduces long- COVID4 Continuous evolution Ongoing antigenic evolution of SARS-CoV-21,2 Risk remains high For severe COVID-19 in vulnerable populations3 Long-Term Need for Annually Adapted Vaccines Anticipated 13 1. World Health Organization Tracking SARS-CoV-2 variant www.who.int/en/activities/tracking-SARS-CoV-2-variants accessed 30 October 2023; 2. Global Initiative on Sharing All Influenza Data https://gisaid.org/ accessed 30 October 2023; 3. FDA Briefing Document Vaccines and Related Biological Products Advisory Committee Meeting June 15, 2023; 4. Brannock et al. Nature Comm. 2023; 5. Stankov M. V. et al. medRxiv pre-print. 2023. SEASONAL VACCINATION Combination vaccines have the potential to provide optimized protection against multiple pathogens in at-risk population
COVID-19 Franchise1: Adaptable Approach in the Face of Dynamic Virus Evolution for Continued Success 14 1. Partnered with Pfizer. Launch of seasonal adapted vaccine If approved, earliest potential introduction of combination respiratory vaccines Expect continued shift to single dose vials and pre-filled syringes Improve Comirnaty properties, e.g., extend shelf half-life 2023 2024 2025 Shift to commercialization model in key markets
15 HSV Malaria Tuberculosis Mpox 3.7 billion people under age 50 globally infected with HSV-2 ~491 million people aged 15-49 infected with HSV-1 worldwide ~249 million cases in 2022 608,000 deaths in 2022 in 85 countries 10.6 million cases globally in 2022 1.3 million deaths globally in 2022 95,000 cases during 22/24 outbreak2 WHO warning about high risk for the general population in DRC Infectious Diseases: Important Clinical Development Area Addressing High Medical and Global Health Need1 1. All figures are from World Health Organization fact sheets unless otherwise referenced https://www.who.int/news-room/fact-sheets (accessed January 04 2024); 2. WHO 2022-24 Mpox outbreak: global trends accessed 09 May 2024 . https://worldhealthorg.shinyapps.io/mpx_global 3. Pan CX, et al. Ther Adv Vaccines Immunother. 2022; 4. Piot P. et al. Nature. 2019. WHO = World Health Organization; HSV = Herpes Simplex Virus; DRC = Democratic Republic of the Congo. Individuals who live to 85 years old have ~50% risk of developing shingles3 Shingles Additional preclinical programs to advance to the clinic in 2024 / 2025
Execution in 2023
O n c o lo g y In fe c ti o u s D is e a s e 8 clinical trials started in 2023 and Q1 2024 Growing clinical stage pipeline 6 clinical assets in-licensed in 2023 3 first-in-human trials started in 2023 10 Phase 2 & 3 trials ongoing Developing an Innovative Pipeline Focused on Oncology and Infectious Disease 17 1. Partnered with Pfizer; 2. In collaboration with Bill & Melinda Gates Foundation; 3. Partnered with the Coalition for Epidemic Preparedness Innovations (CEPI). Tuberculosis2 Shingles1 Mpox3 20+ clinical stage programs 7 clinical stage programs 10 or more potentially registrational clinical trials planned for 2024+ BioNTech’s pipeline Clinical and scientific execution
Corporate Execution in 2023 and Q1 2024 1. Consists of cash and cash equivalents of €8,976.6 million and security investments of €7,962.7 million as of March 31, 2024. AI = artificial intelligence; ADC = antibody drug conjugate; IO = immune oncology; CAR = chimeric antigen receptor 18 Strong cash position ~€ 16.9 bn total cash plus security investments1 Continued progress towards building a multi-product, AI-powered, patient-centric company embedded in the biotech ecosystem Acquired InstaDeep Strategic alliance with AutolusIn-licensed 6 new clinical stage candidates Integrating capabilities in super- computing, AI research and generative AI into various processes Adding new ADCs and next-generation IO antibodies Advancing CAR-T programs towards potential commercialization
BioNTech Today1 1. As of 31 December 2023. United Kingdom London Cambridge Rwanda Kigali BioNTainer Austria Vienna Germany Mainz (HQ) Marburg Idar-Oberstein Neuried Planegg-Martinsried Singapore U.S. Cambridge Gaithersburg China Shanghai Türkiye Istanbul BioNTech locations 19 Australia BioNTainer (planned) >80 different nationalities 36 average age >50 % are female >6,300 professionals globally Founded in 2008 InstaDeep offices
Accelerate and Enhance BioNTech’s AI Vision 20 AI = artificial intelligence; ML = machine learning. Leverage the power of computational science & AI Implementation strategy • Optimize design of product candidates • Speed up workflows to develop novel therapeutics & vaccine product candidates • Scale up our capability by fully digitalized automation throughout the whole drug discovery cycle & Successful collaboration over past three years Define high priority projects Ensure close teamwork at project level Keep integrity of InstaDeep
Healthcare and Social Responsibility 21 1. Tuberculosis program run in collaboration with the Bill & Melinda Gates Foundation, Mpox partnered with the Coalition for Epidemic Preparedness Innovations (CEPI), Malaria wholly owned program; 2. Partnered with Pfizer, 3. As of December 2023. Inaugurated manufacturing facility in Kigali, Rwanda in December 2023, which could become the first commercial-scale mRNA manufacturing facility in Africa Advanced mRNA-based vaccine candidates into the clinic to address global health threats1 >30% of doses of COVID- 19 vaccine delivered to low- and middle-income countries in 20232,3 Contributing to democratizing access to novel medicines around the globe
Outlook 2024
Cash position Respiratory vaccine franchise Oncology pipeline Infectious diseases pipeline Strategic Vision for 2030 23 1. Consists of cash and cash equivalents of €8,976.6 million and security investments of €7,962.7 million as of March 31, 2024. €16.9 bn cash1 Market-leading and cashflow generating More than 20 programs in late-stage clinical development, including first potentially registrational trials Pipeline with 7 programs in early clinical development Maintain strong balance sheet Multi-vaccine portfolio for respiratory diseases Multiple commercial products and additional late-stage candidates First approved products and late-stage pipeline Today 2030 Vision Key value drivers Long-term growth through a diversified, cash flow-generating multi-product portfolio
2 Financial Development 2023 & Q1 2024 and Financial Outlook 2024 Jens Holstein, CFO
FY 2023 Key Financial Figures1 25 Profit before tax € 3.83 € 1.2 bn€ 3.8 bn € 17.7bn Total revenues Diluted EPS 1. Financial information is prepared and presented in Euros and numbers are rounded to millions and billions of Euros in accordance with standard commercial practice; 2. Consists of cash and cash equivalents of €11,663.7 million and security investments of €5,989.7 million as of December 31, 2023. Total cash plus security investments2
FY 2023 Guidance vs. Actuals1 26 COVID-19- vaccine revenues BioNTech COVID-19 vaccine revenues ~ €4 bn €3.8 bn Expenses and capex R&D expenses2 €1,800 – 2,000 m €1,783 m SG&A expenses3 €600 – 650 m €558 m Capital expenditure for operating activities €200 – 300 m €276 m Tax assumptions BioNTech Group estimated annual cash effective income tax rate ~ 21% 21.6% Updated Guidance FY 2023 published in Nov. 2023 FY 2023 Actuals 1. Numbers reflect current base case projections and are calculated based on constant currency rates. Excluding external risks that are not yet known and/or quantifiable, including, but not limited to, the effects of ongoing and/or future legal disputes or related activity; 2. Numbers include effects identified from additional in-licensing arrangements, collaborations or potential M&A transactions to the extent disclosed and are subject to update due to future developments; 3. Excluding costs for external legal advice in connection with certain legal litigations recorded in other operating expense. Guidance does not include and may be impacted by potential payments resulting from the outcomes of ongoing or future legal disputes or related activity, such as judgments or settlements.
FY 2023 Capital Transactions 27 Repurchased ADSs 1 to be held in treasury Period Number of purchased ADSs Percentage of share capital2 Average price Volume Share Repurchase Program 2022 (second tranche 3 ) Jan. to Mar. 2023 2,221,171 0.9% $136.02 $302.1 m Share Repurchase Program 2023 Jun. to Sep. 2023 4,646,965 1.9% $107.58 $500.0 m Total number of purchased ADSs 6,868,136 Use of ADSs held in treasury Period Number of issued ADSs Percentage of share capital2 Issue price Volume ESOP 2018 Settlement May to Nov. 2023 4 328,133 0.1% €96.49 €31.7 m Acquisition of InstaDeep Ltd. Jul. 2023 1,050,569 0.4% €98.69 €103.7 m Total number used ADSs previously held in treasury 1,378,702 1. American Depositary Shares (ADS), each representing one ordinary share; 2. The "percentage of share capital" ratio is calculated based on the shares issued as of December 31, 2023 (248,552,200); 3. Part of the 2022 share repurchase program under which ADSs up to $1.5 billion could be repurchased within two years from May 2, 2022 and under which the first tranche with a value of $1.0 billion ended in October 2022; 4. Since May 8, 2024, treasury shares have again been issued under the ESOP 2018.
Q1 2024 Key Financial Figures1 28 Research & development expenses € (332) m € 508 m€ 188 m € 16.9 bn Total revenues (Loss) before tax Total cash plus security investments2 1. Financial information is prepared and presented in Euros and numbers are rounded to millions and billions of Euros in accordance with standard commercial practice; 2. Consists of cash and cash equivalents of €8,976.6 million and security investments of €7,962.7 million as of March 31, 2024.
2024 Financial Year Guidance Reiterated1 29 Revenue guidance consideration: Top-line sensitivity mainly dependent on the following factors • Vaccination rates and price levels in markets where significant Comirnaty sales are expected • Inventory write-downs • Anticipated revenues related to service businesses, including InstaDeep, JPT Peptide Technologies, IMFS and from the German pandemic preparedness agreement 1. Excluding external risks that are not yet known and/or quantifiable, including, but not limited to, the effects of ongoing and/or future legal disputes or related activity; 2. Numbers include effects identified from additional in-licensing arrangements, collaborations or potential M&A transactions to the extent disclosed and are subject to update due to future developments; 3. Anticipated expenses related to external legal advice in connection with legal litigations is not reflected in SG&A but in other operating expenses for the 2024 financial year. Guidance does not include and may be impacted by potential payments resulting from the outcomes of ongoing or future legal disputes or related activity, such as judgments or settlements; 4. The Company does not expect to report a positive net income figure for the 2024 financial year and expects the majority of our 2024 global revenues for Comirnaty to be recorded in the second half of the year. IMFS = BioNTech’s Innovative Manufacturing Services GmbH FY 2024 revenues Total revenues €2,500 – 3,100 m FY 2024 expenses, operating income and capex4 R&D expenses2 €2,400 – 2,600 m SG&A expenses3 €700 – 800 m Capital expenditure for operating activities €400 – 500 m FY 2024 Guidance
Save the date Innovation Series: AI Day October 1, 2024 Annual Innovation Series November 14, 2024
Thank you for your attention.
Voting results - Overview BioNTech SE, Mainz ordinary Annual General Meeting on 17/05/2024 Page 1Note: Percentages rounded to 2 decimal places Valid votes cast Yes votes No votes Shares % of capital stock Shares % Shares % Item 2 Resolution on the Appropriation of Balance Sheet Profit for the 2023 Financial Year 217,475,666 87.50 % 217,364,146 99.95 % 111,520 0.05 % Item 3 Resolution on the Approval of the Actions of the Management Board 177,450,928 71.39 % 177,279,149 99.90 % 171,779 0.10 % Item 4 Resolution on the Approval of the Actions of the Supervisory Board 214,986,400 86.50 % 212,475,898 98.83 % 2,510,502 1.17 % Item 5 Resolution on the Appointment of the Auditor of the Annual Financial Statements and the Auditor of the Consolidated Financial Statements for the 2024 Financial Year as well as the Auditor for any Audit or Review of Interim Financial Information During the Year 217,482,977 87.50 % 216,757,573 99.67 % 725,404 0.33 % Item 6 Resolution on the Approval of the Compensation Report 217,481,023 87.50 % 208,829,552 96.02 % 8,651,471 3.98 % Item 7 Resolution on the approval of the adjusted Compensation System for members of the Management Board 217,482,702 87.50 % 211,676,453 97.33 % 5,806,249 2.67 % Item 8 Resolution on the Adjustment of the Compensation System and the Compensation of the Supervisory Board members as well as the corresponding Amendment to Art. 9 para. 6 of the Articles of Association 217,478,894 87.50 % 212,415,111 97.67 % 5,063,783 2.33 % Item 9 Resolution on the Cancellation of an existing Authorization and the Creation of a new Authorization to issue Bonds with warrants and/or Convertible Bonds and to exclude Subscription Rights, together with the simultaneous Cancellation of the existing Conditional Capital WSV 2019 and the Creation of new Conditional Capital WSV 2024 as well as a corresponding Amendment to the Articles of Association 217,467,951 87.49 % 211,471,422 97.24 % 5,996,529 2.76 % Item 10 Resolution on the Authorization to acquire Treasury Shares, also excluding Tender Rights, and to use them, also excluding Subscription Rights, as well as the Cancellation of the existing Authorization 217,445,891 87.48 % 217,142,950 99.86 % 302,941 0.14 % Item 11 Resolution on the Authorization to use Derivatives in connection with the Acquisition of Treasury Shares 217,434,396 87.48 % 217,118,497 99.85 % 315,899 0.15 % Exhibit 99.3
Voting results - Overview BioNTech SE, Mainz ordinary Annual General Meeting on 17/05/2024 Page 2Note: Percentages rounded to 2 decimal places Valid votes cast Yes votes No votes Shares % of capital stock Shares % Shares % Item 12 Amendment of authorizations to issue Stock Options 217,482,638 87.50 % 217,152,276 99.85 % 330,362 0.15 % Item 13 Resolution on the partial Cancellation of the Conditional Capital ESOP 2017/2019, the partial Cancellation and Amendment of an Authorization to issue Stock Options (ESOP 2021) as well as on the partial Cancellation of the Conditional Capital ESOP 2021, a new authorization to issue Stock Options (ESOP 2024) and the Creation of a new Conditional Capital ESOP 2024 and corresponding Amendments to the Articles of Association 217,459,429 87.49 % 216,577,888 99.59 % 881,541 0.41 % Item 14 Resolution on the approval of the conclusion of a Domination and Profit and Loss Transfer Agreement between BioNTech SE and BioNTech Collaborations GmbH 217,467,268 87.49 % 217,415,742 99.98 % 51,526 0.02 %